Improved outcome in childhood ALL with intensive consolidation and hematopoietic stem cell transplant.
10.5045/kjh.2010.45.2.109
- Author:
Jeong A PARK
1
;
Thad GHIM
;
Keun Wook BAE
;
Kyung Nam KOH
;
Ho Joon IM
;
Jong Jin SEO
Author Information
1. Department of Pediatric, Inje University Haeundae Baik Hospital, Inje University College of Medicine, Busan, Korea.
- Publication Type:Original Article
- Keywords:
Acute lymphoblastic leukemia;
Relapse;
Intensive consolidation;
Hematopoietic stem cell transplantation
- MeSH:
Bone Marrow;
Child;
Consolidation Chemotherapy;
Disease-Free Survival;
Hematopoietic Stem Cell Transplantation;
Hematopoietic Stem Cells;
Humans;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
Prognosis;
Recurrence;
Transplants
- From:Korean Journal of Hematology
2010;45(2):109-114
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Despite advances in chemotherapy, the prognosis of relapsed acute lymphoblastic leukemia (ALL) remains poor. Few studies on relapsed ALL have reported the importance of intensive consolidation followed with or without allogeneic hematopoietic stem cell transplantation (HSCT). METHODS: We evaluated the post-relapse outcomes in 47 Korean children with a first marrow relapse, and analyzed the prognostic factors. RESULTS: A second complete remission (CR) was achieved in 40 patients (85.1%), and at the time of this study, second CR was maintained in 12 of these patients. The estimated 3-yr event-free survival (EFS) rate after the first marrow relapse was 29.8+/-6.7%, and the overall survival (OS) rate was 45.3+/-7.5%. We found that second remission, consolidation of pediatric oncology group chemotherapy regimen (POG 9411), and HSCT significantly affected the outcome of the disease after relapse (P<0.001; P=0.004; P=0.05). CONCLUSION: The results of our study revealed that an intensified POG 9411 consolidation chemotherapy regimen followed by HSCT can improve the outcome of patients with relapsed ALL.
